menu
    • menu
    [{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AT-7687","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Antag Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antag Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antag Therapeutic \/ Undisclosed"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2024","type":"Series A Financing","leadProduct":"AT-7687","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Antag Therapeutic","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Antag Therapeutic \/ Versant Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Antag Therapeutic \/ Versant Ventures"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AT-7687","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Antag Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Antag Therapeutic \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Antag Therapeutic \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Antag Therapeutic

    Menu

    Antag Therapeutic

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Antag Therapeutic

                            Denmark arrow
                            FNCE
                            Not Confirmed

                            Antag Therapeutic

                            Denmark arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-7687

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antag Starts Phase 1a Trial of GIPR Antagonist AT-7687 for Obesity

                            Details : AT-7687 is a peptide GIP receptor antagonist designed for once-weekly subcutaneous, currently, it is being evaluated in the treatment of obesity.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 02, 2025

                            Lead Product(s) : AT-7687

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Antag Therapeutic

                            Denmark arrow
                            FNCE
                            Not Confirmed

                            Antag Therapeutic

                            Denmark arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-7687

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Versant Ventures

                            Deal Size : $84.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Antag Therapeutics Announces €80 Million Series A Financing

                            Details : The proceeds from the financing will be used for the development of Antag's lead molecule AT-7687. It is a peptide designed to be co-administrated with current or future obesity therapies.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            December 04, 2024

                            Lead Product(s) : AT-7687

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Versant Ventures

                            Deal Size : $84.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Antag Therapeutic

                            Denmark arrow
                            FNCE
                            Not Confirmed

                            Antag Therapeutic

                            Denmark arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-7687

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antag Receives FDA Clearance For IND Application For AT-7687

                            Details : AT-7687 is a peptide GIP receptor antagonist designed for once-weekly subcutaneous, currently, it is being evaluated in the treatment of obesity.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 09, 2024

                            Lead Product(s) : AT-7687

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth